
    
      The study completed a dose escalation phase, and is now enrolling in a dose expansion phase
      to further characterize the safety profile and to assess the efficacy of IMGN632 in patients
      with BPDCN. IMGN632 is administered by IV on Day 1 of each cycle, with cycles repeating every
      21 days.
    
  